Si-Bone (SIBN) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.24. This compares to loss of $0.27 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of 37.50%. A quarter ago, it was expected that this medical device maker would post a loss of $0.16 per share when it actually produced a loss of $0.11, delivering a surprise of 31.25%.Over the last four quarters, the company has sur ...

Core Viewpoint - Standex International (SXI) reported quarterly earnings of $1.95 per share, exceeding the Zacks Consensus Estimate of $1.93 per share, and showing an increase from $1.75 per share a year ago, indicating a positive earnings surprise of 1.04% [1] Financial Performance - The company achieved revenues of $207.78 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 1.33%, compared to $177.27 million in the same quarter last year [2] - Over the last four quarters, Standex has consistently surpassed consensus EPS estimates four times and topped revenue estimates two times [2] Stock Performance and Outlook - Standex shares have declined approximately 24.4% since the beginning of the year, contrasting with the S&P 500's decline of 5.3% [3] - The company's future stock performance will largely depend on management's commentary during the earnings call and the trends in earnings estimate revisions [3][4] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is $2.33 on revenues of $220.56 million, and for the current fiscal year, it is $7.86 on revenues of $785.88 million [7] - The estimate revisions trend for Standex is currently mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Manufacturing - General Industrial industry, to which Standex belongs, is currently ranked in the bottom 41% of over 250 Zacks industries, suggesting potential challenges ahead [8]

分组1 - Blueprint Medicines reported a quarterly loss of $0.74 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.42, representing an earnings surprise of -76.19% [1] - The company posted revenues of $149.41 million for the quarter ended March 2025, missing the Zacks Consensus Estimate by 8.04%, but showing an increase from $96.12 million in the same quarter last year [2] - The current consensus EPS estimate for the upcoming quarter is -$0.46 on revenues of $171.35 million, and for the current fiscal year, it is -$1.01 on revenues of $728.21 million [7] 分组2 - The Zacks Industry Rank for Medical - Biomedical and Genetics is in the top 32% of over 250 Zacks industries, indicating a favorable outlook for the industry [8] - Blueprint Medicines shares have increased by approximately 2.6% since the beginning of the year, contrasting with a -5.3% decline in the S&P 500 [3] - The estimate revisions trend for Blueprint Medicines is currently mixed, resulting in a Zacks Rank 3 (Hold), suggesting the stock is expected to perform in line with the market in the near future [6]

Core Viewpoint - Atmos Energy Corporation (ATO) is expected to report its second-quarter fiscal 2025 results on May 7, with an earnings surprise of 1.4% in the previous quarter [1] Group 1: Factors Impacting Q2 Earnings - Strategic investments and modernization of transmission and distribution systems are likely to have positively impacted the company's bottom line [2] - An expanding customer base and implementation of new rates in service regions are expected to contribute positively to earnings [3] - Higher distribution revenues and lower interest expenses are anticipated to further benefit the quarterly performance [3] - However, increased operation and maintenance expenses, along with higher depreciation and amortization, may have negatively affected the bottom line [4] Group 2: Q2 Expectations - The Zacks Consensus Estimate for earnings is $2.89 per share, reflecting a year-over-year increase of 1.4% [5] - The revenue estimate stands at $1.88 billion, indicating a year-over-year improvement of 14.4% [5] Group 3: Earnings Prediction - The company's Earnings ESP is +1.33%, suggesting a strong likelihood of an earnings beat [6] - Atmos Energy currently holds a Zacks Rank 2 (Buy), which supports the prediction of an earnings beat [7]

Company Performance - LSB reported a quarterly loss of $0.02 per share, matching the Zacks Consensus Estimate, compared to earnings of $0.12 per share a year ago, representing an earnings surprise of -200% [1] - The company posted revenues of $143.43 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 7.04%, and an increase from year-ago revenues of $138.2 million [2] - Over the last four quarters, LSB has surpassed consensus EPS estimates just once, but has topped consensus revenue estimates three times [2] Stock Performance - LSB shares have declined approximately 22.4% since the beginning of the year, while the S&P 500 has decreased by 6% [3] - The current consensus EPS estimate for the upcoming quarter is $0.23 on $154 million in revenues, and $0.27 on $551.05 million in revenues for the current fiscal year [7] Industry Outlook - The Zacks Industry Rank for Chemical - Diversified is currently in the bottom 15% of over 250 Zacks industries, indicating potential challenges for stock performance [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact LSB's stock performance [5]

There are no easy answers to this key question, but one reliable measure that can help investors address this is the company's earnings outlook. Not only does this include current consensus earnings expectations for the coming quarter(s), but also how these expectations have changed lately. PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.45 per share versus the Zacks Consensus Estimate of a loss of $0.49. This compares to loss of $0.51 per share a year ago. These figures are adju ...

Core Insights - Tri Pointe Homes (TPH) reported quarterly earnings of $0.70 per share, exceeding the Zacks Consensus Estimate of $0.45 per share, but down from $1.03 per share a year ago, representing an earnings surprise of 55.56% [1] - The company achieved revenues of $720.79 million for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 2.58%, but down from $918.35 million year-over-year [2] - Tri Pointe shares have declined approximately 14.8% year-to-date, compared to a decline of 8.6% for the S&P 500 [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is $0.76, with expected revenues of $916.33 million, and for the current fiscal year, the EPS estimate is $3.10 on revenues of $3.81 billion [7] - The estimate revisions trend for Tri Pointe is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market [6] Industry Context - The Building Products - Home Builders industry is currently ranked in the bottom 29% of over 250 Zacks industries, suggesting potential challenges for stocks in this sector [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]

Northrim BanCorp (NRIM) came out with quarterly earnings of $2.38 per share, beating the Zacks Consensus Estimate of $1.56 per share. This compares to earnings of $1.48 per share a year ago. These figures are adjusted for non-recurring items. This quarterly report represents an earnings surprise of 52.56%. A quarter ago, it was expected that this holding company for Northrim Bank would post earnings of $1.70 per share when it actually produced earnings of $1.95, delivering a surprise of 14.71%. There are no ...

First Bank (FRBA) came out with quarterly earnings of $0.37 per share, missing the Zacks Consensus Estimate of $0.39 per share. This compares to earnings of $0.49 per share a year ago. These figures are adjusted for non- recurring items. This quarterly report represents an earnings surprise of -5.13%. A quarter ago, it was expected that this company would post earnings of $0.39 per share when it actually produced earnings of $0.42, delivering a surprise of 7.69%. While First Bank has outperformed the market ...

Core Viewpoint - Omnicom reported quarterly earnings of $1.70 per share, exceeding the Zacks Consensus Estimate of $1.63 per share, and showing a slight increase from $1.67 per share a year ago, indicating a positive earnings surprise of 4.29% [1][2] Financial Performance - The company achieved revenues of $3.69 billion for the quarter ended March 2025, surpassing the Zacks Consensus Estimate by 0.15% and reflecting a year-over-year increase from $3.63 billion [2] - Over the last four quarters, Omnicom has consistently surpassed consensus EPS estimates and revenue estimates [2] Stock Performance and Outlook - Omnicom shares have declined approximately 11% since the beginning of the year, compared to an 8.1% decline in the S&P 500 [3] - The company's current Zacks Rank is 4 (Sell), indicating expectations of underperformance in the near future [6] Future Earnings Expectations - The consensus EPS estimate for the upcoming quarter is $2.07 on revenues of $3.95 billion, while the estimate for the current fiscal year is $8.31 on revenues of $16.01 billion [7] - The trend of estimate revisions for Omnicom has been unfavorable leading up to the earnings release [6] Industry Context - The Advertising and Marketing industry, to which Omnicom belongs, is currently ranked in the bottom 40% of over 250 Zacks industries, suggesting potential challenges ahead [8]